Table Filtering
Other Information
Release Statistics Download
GlyCosmos Glycolipids

Glycolipid entries from the LIPID MAPS Structure Database (LMSD).

Source Last Updated
LIPID MAPS Proteome Database (LMSD) June 16, 2024
Displaying entries 2976 - 3000 of 6046 in total
Sub Class LM ID Name LipidBank ID KEGG ID PubChem CID ChEBI ID Exact Mass ▼ Formula
Gangliosides LMSP0601CQ01
  • GD1a (NeuGc/NeuGc)(d18:1/16:0)
  • NeuGcalpha2-3Galbeta1-3GalNAcbeta1-4(NeuGcalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/16:0)
44262492 1840.930611 C82H144N4O41
Gangliosides LMSP0601FG01
  • NeuGcalpha2-8NeuGcalpha2-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
44262988 1840.930611 C82H144N4O41
Gangliosides LMSP0601DE05
  • KDNGD1a(d18:1/24:0)
  • KDNalpha2-3Galbeta1-3GalNAcbeta1-4(KDNalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44262592 1839.012883 C86H154N2O39
Gangliosides LMSP0601DI05
  • KDN GD1a 2(d18:1/24:0)
  • KDNalpha2-3Galbeta1-3(KDNalpha2-6)GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44262624 1839.012883 C86H154N2O39
Diacylglycerophosphoinositolglycans LMGP15010258
  • 2'-O-(alpha-D-Manp)-6'-O-(alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp)-(1,2-dioctadecanoyl-sn-glycero-3-phospho-1'-myo-inositol)
  • PIM6(18:0/18:0)
126457626 1838.905383 C81H147O43P
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AG04
  • Galbeta1-3(Galbeta1-4GlcNAcbeta1-6)GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/22:0)
44260215 1838.028867 C86H155N3O38
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505BL04
  • Galalpha1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/22:0)
44261271 1838.028867 C86H155N3O38
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AK06
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0)
  • type IV B antigen(d18:1/26:0)
44260249 1837.070003 C88H160N2O37
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BC06
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/26:0)
44261649 1837.070003 C88H160N2O37
Gangliosides LMSP0601DE07
  • KDNGD1a(d18:1/24:1(15Z))
  • KDNalpha2-3Galbeta1-3GalNAcbeta1-4(KDNalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44262594 1836.997233 C86H152N2O39
Gangliosides LMSP0601DI07
  • KDN GD1a 2(d18:1/24:1(15Z))
  • KDNalpha2-3Galbeta1-3(KDNalpha2-6)GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44262626 1836.997233 C86H152N2O39
Gangliosides LMSP0601AQ02
  • GD1b(d18:1/18:0)
  • Galbeta1-3GalNAcbeta1-4(NeuAcalpha2-8NeuAcalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44262093 90238 1836.972081 C84H148N4O39
Gangliosides LMSP0601AS02
  • GD1a(d18:1/18:0)
  • NeuAcalpha2-3Galbeta1-3GalNAcbeta1-4(NeuAcalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44262109 84656 1836.972081 C84H148N4O39
Gangliosides LMSP0601BA02
  • GD1e(d18:1/18:0)
  • NeuAcalpha2-3Galbeta1-3(NeuAcalpha2-6)GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44262173 1836.972081 C84H148N4O39
Gangliosides LMSP0601BE02
  • GD1aa(d18:1/18:0)
  • Galbeta1-3(NeuAcalpha2-6)GalNAcbeta1-4(NeuAcalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44262205 1836.972081 C84H148N4O39
Gangliosides LMSP0601BN02
  • GD1c(d18:1/18:0)
  • NeuAcalpha2-8NeuAcalpha2-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44262277 1836.972081 C84H148N4O39
Gangliosides LMSP0601DT02
  • NeuAcalpha2-8NeuAcalpha2-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44262701 1836.972081 C84H148N4O39
Gangliosides LMSP0601DU02
  • NeuAcalpha2-3Galbeta1-3(NeuAcalpha2-6)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44262709 1836.972081 C84H148N4O39
Gangliosides LMSP0601EG02
  • NeuAcalpha2-8NeuAcalpha2-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44262797 1836.972081 C84H148N4O39
Gangliosides LMSP0601GM02
  • Galbeta1-3(NeuAcalpha2-8NeuAcalpha2-6)GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44263221 1836.972081 C84H148N4O39
Diacylglycerophosphoinositolglycans LMGP15010259
  • 2'-O-(alpha-D-Manp)-6'-O-(alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp)-(1-octadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-1'-myo-inositol)
  • PIM6(18:0/18:1(9Z))
126457627 1836.889733 C81H145O43P
Diacylglycerophosphoinositolglycans LMGP15010264
  • 2'-O-(alpha-D-Manp)-6'-O-(alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp)-(1-(9Z-octadecenoyl)-2-octadecanoyl-sn-glycero-3-phospho-1'-myo-inositol)
  • PIM6(18:1(9Z)/18:0)
126457632 1836.889733 C81H145O43P
Gangliosides LMSP0601AF06
  • NeuGcalpha2-3Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0)
44262009 1836.049602 C87H157N3O37
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AK08
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
  • type IV B antigen(d18:1/26:1(17Z))
44260251 1835.054353 C88H158N2O37
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BC08
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44261651 1835.054353 C88H158N2O37

About Release Notes Help Feedback

Click here to visit the beta site.


International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01


Logo License Policies Site Map

Contact: support@glycosmos.org

This work is licensed under Creative Commons Attribution 4.0 International


GlyCosmos Portal v4.0.0

Last updated: August 19, 2024